BAUSCH + LOMB CORP

NYSE: BLCO (Bausch + Lomb Corporation)

最近更新时间: 15 Sep, 1:23AM

15.19

-0.13 (-0.85%)

前收盘价格 15.32
收盘价格 15.26
成交量 310,268
平均成交量 (3个月) 757,438
市值 5,393,847,296
预期市盈率 (P/E Forward) 13.39
价格/销量 (P/S) 1.06
股市价格/股市净资产 (P/B) 0.810
52周波幅
10.45 (-31%) — 21.69 (42%)
利润日期 29 Oct 2025
营业毛利率 -7.50%
营业利益率 (TTM) -5.36%
稀释每股收益 (EPS TTM) -1.02
季度收入增长率 (YOY) 3.50%
总债务/股东权益 (D/E MRQ) 75.07%
流动比率 (MRQ) 1.56
营业现金流 (OCF TTM) 166.00 M
杠杆自由现金流 (LFCF TTM) 69.00 M
资产报酬率 (ROA TTM) 0.61%
股东权益报酬率 (ROE TTM) -5.36%

市场趋势

短期 中期
行业 Medical Instruments & Supplies (US) 混合的 混合的
Medical Instruments & Supplies (全球的) 混合的 看跌
股票 Bausch + Lomb Corporation 看涨 看跌

AIStockmoo 评分

-0.6
分析师共识 1.5
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 -2.5
技术振荡指标 -0.5
平均 -0.63

相关股票

股票 市值 DY P/E(TTM) P/B
BLCO 5 B - - 0.810
BDX 54 B 1.11% 34.21 2.16
WST 16 B 0.28% 34.84 6.71
AVTR 8 B - 12.33 1.49
ALC 37 B 0.35% 34.77 1.68
RMD 40 B 0.39% 28.53 6.77

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

部门 Healthcare
行业 Medical Instruments & Supplies
投资方式 Mid Core
内部持股比例 88.13%
机构持股比例 10.97%
52周波幅
10.45 (-31%) — 21.69 (42%)
目标价格波幅
13.00 (-14%) — 17.00 (11%)
17.00 (Evercore ISI Group, 11.92%) 购买
16.00 (5.33%)
13.00 (Morgan Stanley, -14.42%) 保留
平均值 15.40 (1.38%)
总计 2 购买, 3 保留
平均价格@调整类型 14.02
公司 日期 目标价格 调整类型 价格@调整类型
Evercore ISI Group 07 Oct 2025 17.00 (11.92%) 购买 14.66
Goldman Sachs 01 Oct 2025 16.00 (5.33%) 保留 14.67
Morgan Stanley 01 Aug 2025 13.00 (-14.42%) 保留 13.50
HC Wainwright & Co. 31 Jul 2025 16.00 (5.33%) 购买 13.63
Wells Fargo 31 Jul 2025 15.00 (-1.25%) 保留 13.63

该时间范围内无数据。

日期 类型 细节
09 Oct 2025 公告 Bausch Health Announces Results of Special Meeting of Shareholders
30 Sep 2025 公告 Bausch Health's Aesthetic Business, Solta Medical, Brings Non-Invasive Aesthetic Innovations to National TV
30 Sep 2025 公告 Bausch Health to Announce Third Quarter 2025 Results on October 29
29 Sep 2025 公告 Bausch Health's OraPharma Introduces "OraTalks," a New Podcast Bringing Bold Conversations to Dentistry
29 Sep 2025 公告 Bausch + Lomb Will Release Third-Quarter 2025 Financial Results on Oct. 29 and Hold Investor Day on Nov. 13
11 Sep 2025 公告 Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
11 Sep 2025 公告 Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
11 Sep 2025 公告 Bausch + Lomb Announces Publication of enVista Envy™ Full Range of Vision Intraocular Lens Pivotal U.S. Clinical Trial
09 Sep 2025 公告 Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers
08 Sep 2025 公告 Bausch + Lomb Launches ASANA™ Gas Permeable Lenses in the United States
05 Sep 2025 公告 Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System
26 Aug 2025 公告 Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025
21 Aug 2025 公告 Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan
18 Aug 2025 公告 Bausch + Lomb Announces Board Changes
15 Aug 2025 公告 Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
14 Aug 2025 公告 Bausch + Lomb to Participate in Upcoming Investor Conferences
30 Jul 2025 公告 Bausch + Lomb Announces Second-Quarter 2025 Results
29 Jul 2025 公告 Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票